Daiichi Sankyo

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Daiichi Sankyo and other ETFs, options, and stocks.

About DSNKY

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. 

CEO
Hiroyuki Okuzawa
CEOHiroyuki Okuzawa
Employees
19,765
Employees19,765
Headquarters
Tokyo, Tokyo
HeadquartersTokyo, Tokyo
Founded
2005
Founded2005
Employees
19,765
Employees19,765

DSNKY Key Statistics

Market cap
45.14B
Market cap45.14B
Price-Earnings ratio
23.59
Price-Earnings ratio23.59
Dividend yield
1.55%
Dividend yield1.55%
Average volume
156.00K
Average volume156.00K
High today
$24.85
High today$24.85
Low today
$23.58
Low today$23.58
Open price
$24.36
Open price$24.36
Volume
26.00K
Volume26.00K
52 Week high
$33.21
52 Week high$33.21
52 Week low
$20.92
52 Week low$20.92

DSNKY News

Nasdaq 19h
Daiichi Sankyo H1 Earnings Down, Cuts FY Earnings View, Lifts Revenue Forecast; Stock Down

(RTTNews) - Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) on Friday trimmed its earnings forecast for full-year ending March 31, 2026, after repor...

Daiichi Sankyo H1 Earnings Down, Cuts FY Earnings View, Lifts Revenue Forecast; Stock Down
TipRanks 4d
Daiichi Sankyo’s Latest Clinical Trial: A Potential Game-Changer for Prostate Cancer Treatment

Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 5...

TipRanks 4d
Daiichi Sankyo’s Promising Study on Innovative Lung Cancer Treatments

Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50%...

More DSNKY News

TipRanks 4d
Daiichi Sankyo’s Latest NSCLC Study: A Potential Game-Changer?

Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 5...

TipRanks 4d
Daiichi Sankyo’s Promising HER2 Positive Breast Cancer Study: Market Insights

Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50%...

TipRanks 4d
Daiichi Sankyo’s New Study on Cardiovascular Drug Combination: A Market Game-Changer?

Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50%...

TipRanks 4d
Daiichi Sankyo’s CLEAR Taiwan Study: A Potential Game-Changer for Cholesterol Management

Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 5...

TipRanks 4d
Daiichi Sankyo’s Latest Study: Insights into Triple-Negative Breast Cancer Care

Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50%...

TipRanks 4d
Daiichi Sankyo’s Real-World Study on Trastuzumab Deruxtecan: Market Implications

Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 5...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.